Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRYAB | P02511 | 6/20 | 1.00 |
| ▸ | CRYAA | P02489 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | PTGES | O14684 | 2/20 | 0.58 |
| ▸ | FNTA | P49354 | 1/20 | 0.54 |
| ▸ | FNTB | P49356 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19194245 | 1.00 | CRYAB (1.00) | CRYABCRYAAUSP2ALDH1A1CYP3A4 | |
| SCHEMBL19181546 | 1.00 | CRYAB (1.00) | CRYABCRYAAUSP2ALDH1A1CYP3A4 | |
| SCHEMBL19194136 | 0.93 | CRYAB (0.87) | CRYABCRYAAUSP2ALDH1A1CYP3A4 | |
| SCHEMBL19198474 | 0.89 | CRYAB (0.80) | CRYABCRYAAUSP2ALDH1A1CYP3A4 | |
| SCHEMBL568417 | 0.89 | CRYAB (0.80) | CRYABCRYAAUSP2ALDH1A1CYP3A4 | |
| SCHEMBL7527661 | 0.89 | CRYAB (0.80) | CRYABCRYAAUSP2ALDH1A1CYP3A4 | |
| SCHEMBL288307 | 0.89 | CRYAB (0.80) | CRYABCRYAAUSP2ALDH1A1CYP3A4 | |
| SCHEMBL6130528 | 0.89 | CRYAB (0.80) | CRYABCRYAAUSP2ALDH1A1CYP3A4 | |
| SCHEMBL288306 | 0.89 | CRYAB (0.80) | CRYABCRYAAUSP2ALDH1A1CYP3A4 | |
| SCHEMBL13499192 | 0.89 | CRYAB (0.80) | CRYABCRYAAUSP2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108884126-B | Compounds for treating eye disorders or diseases | 广州康睿生物医药科技股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-10093694-B2 | Compounds for treating eye disorders or diseases | GUANGZHOU KANGRUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGY CO, LTD. (CN) | 2018-10-09 | — | — | US | disclosed |
| US-20170218009-A1 | COMPOUNDS FOR TREATING EYE DISORDERS OR DISEASES | GUANGZHOU KANGRUI BIOLOGICAL PHARMACEUTICAL TECHNOLOGIES CO., LTD. (CN) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093694-B2 | Compounds for treating eye disorders or diseases | UACA, CRYAA, CLN6 | CRYAB 4/4885CRYAA 2/4885USP2 915/4885 |
| US-20170218009-A1 | COMPOUNDS FOR TREATING EYE DISORDERS OR DISEASES | UACA, CRYAA, CLN6 | CRYAB 4/4885CRYAA 2/4885USP2 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.